If you have been reading about lipolysis and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
The quality of gamma-camera PET imaging is lower, and the scans take longer to acquire. Alternative methods of medical imaging include single-photon emission computed tomography (SPECT), computed tomography (CT), magnetic resonance imaging (MRI) and functional magnetic resonance imaging (fMRI), and ultrasound. SPECT is an imaging technique similar to PET that uses radioligands to detect molecules in the body.
Extrapyramidal signs Rhabdomyolysis, acute Ataxia Irregular heart beat Mild hypothyroidism Loss of milestones Delayed speech and language acquisition Delayed walking Abnormal liver enzymes Gastrointestinal dysmotility Generalised brain atrophy High blood ammonia levels Low blood sugar Involuntary muscle contractions Increased lactate in body Prolonged QT interval Seizure Occasional:
The stalemate ended when a seven-figure sum was paid for him and the duo to be released from Def Jam before signing a distribution deal with Roc Nation instead, although Def Jam will receive a portion of the album's revenue. The distribution deal, spearheaded by Jay-Z, was finalized less than a full day after Clipse left Def Jam. The latter signing was informally announced in May 2025 when a picture of the duo in front of the Roc Nation insignia, captioned with the album title, was posted to Instagram jointly by the duo and Roc Nation itself.
Sources: en.wikipedia.org
The two studies where inconclusive for other outcome measures (including all-cause and cardiovascular mortality, non‐fatal myocardial infarction, non‐fatal stroke, congestive heart failure, serious and non‐serious adverse events (increased “non‐serious side effects” where concluded only for acarbose), hypoglycaemia, measures of blood glucose control, blood lipids, body weight, and blood pressure).
). The alternative notation also makes it straightforward to see how the GTR model can be applied to biological alphabets with a larger state-space (e.g., amino acids or codons). It is possible to write a set of equilibrium state frequencies as
Cuba and the Soviet Union were not consulted on the Lusaka Accords until after they had been signed. In a heated exchange with President dos Santos, Fidel Castro complained, "the final decision was yours, not ours, but at least we could have talked beforehand, and we, as well as the Soviets, could have expressed our disagreement beforehand...both the Soviets and us, your two main allies, the two who support Angola, who have been making immense efforts on your behalf, we were faced with a fait accompli". UNITA denounced the Lusaka Accords, insisting that any peace effort which excluded it would fail. PLAN also routinely violated the disengagement area, prompting the SADF to delay and later cancel its withdrawal. In July 1984 South Africa formally announced that it would not withdraw from Angola, citing widespread PLAN activity in the border region.
She cuts ties with Otto and brings Eric out of retirement to launch SternTao, targeting fintech company Tender. After a one-night stand with Tender CFO Whitney Halberstram, Harper is tipped off by journalist James Dycker that Tender is concealing misconduct. She hires Sweetpea and Kwabena Bannerman—her former colleague and casual partner—and sends them to Accra to investigate Tender’s acquisitions, where they uncover falsified profits and recycled revenue. Harper presents the findings at an investment conference, causing Tender’s stock to fall 28%. During this period, she learns her estranged mother has died and struggles to grieve amid her work. Eric later transfers his ownership stake in SternTao to her and withdraws from the partnership without explanation, having been blackmailed, leaving Harper devastated. She reconciles with Yasmin after helping circulate claims that the Labour government suppressed concerns about Tender, prompting investigations and a new audit. The Tender short ultimately earns SternTao £110 million, and Harper, Sweetpea, and Kwabena scout a new office. In Paris, Harper attends a fundraiser hosted by Yasmin for Reform MP Sebastian Stefanowicz and is disturbed by the guests (including the Nazi-sympathizing Bauer family) and Yasmin's use of escorts; Yasmin shows her a compromising recording of Eric with an underage prostitute, leaving Harper shaken. She later reflects on the Tender short in an interview with journalist Patrick Radden Keefe and ponders her future.
Sources: en.wikipedia.org
Decay modes in parentheses are given for observationally stable nuclides (these and these); they are then those allowed to occur by energy (in the next column), but spontaneous fission (and cluster decay, which is never shown in the tables) are neglected as they should never be observed for these nuclides. Those with multiple significant decay modes have the probability of each decay mode in percent given, in small figures, in parentheses; those less than 0.05% are rounded to zero and omitted, and 100 (>99.5% of observed decays) is not used but replaced by bold unless the only other decays are SF or double beta, assumed to be minority decays if not listed first. If more than one of α, β−, β+/ε, IT is given without numbers or bold, one can assume no experimental data is available. Note that, by widely used convention, β+ (technically positron emission) includes ε, and conversely, if positron emission is energetically possible; the two are never separated on this page.
== Clinical significance == Variations in the CRHR1 gene is associated with enhanced response to inhaled corticosteroid therapy in asthma. CRF1 triggers cells to release hormones that are linked to stress and anxiety [original reference missing]. Hence CRF1 receptor antagonists are being actively studied as possible treatments for depression and anxiety. Variations in CRHR1 are associated with persistent pulmonary hypertension of the newborn.
About half of all cases are inherited from a parent who has the condition. The condition is inherited in an autosomal dominant pattern, which means only one copy of the altered gene is necessary to cause the disorder. The other half of cases occur in patients whose families have no history of the disorder. These sporadic cases are caused by new mutations in one copy of the COL3A1 gene. The protein determined by the COL3A1 gene is used to assemble larger type III collagen molecules, found mostly in skin, blood vessels, and internal organs. When the structure or production of type III collagen is altered by a mutation in the COL3A1 gene, collagen fibrils cannot be assembled properly in these tissues, which causes the symptoms of Ehlers-Danlos syndrome.
== See also == Alexis St. Martin – Canadian subject of digestion experiments (1802–1880) Fistulated cow M. Ijaiya's technique – Surgical procedure to close juxtacervical vesicovaginal fistulae Obstetric fistula Stoma (medicine)
Specifically, some studies show evidence of components of the glyoxylate cycle existing in significant amounts in the liver tissue of chickens. Data such as these support the idea that the cycle could theoretically occur in even the most complex vertebrates. There is strong evidence of the cycle's presence in certain nematode species. Other experiments, later refuted, suggested the cycle was present among certain insect and marine invertebrate species. Some publications conflict on the presence of the cycle in mammals: for example, one paper has stated that the glyoxylate cycle is active in hibernating bears, but this report was disputed in a later paper. Evidence exists for malate synthase activity in humans due to a dual functional malate/B-methylmalate synthase of mitochondrial origin called CLYBL expressed in brown fat and kidney. Vitamin D may regulate this pathway in vertebrates.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.